

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)	Examiner: F. VanderVegt		
Sam D. Sanderson et al.)	Construction 1644		
Application No. 09/051,685)	Group Art Unit: 1644		
Filed: August 19, 1998)	Response to Paper No. 11		
For:	Compositions and Methods for Enhancing Immune Responses Mediated by Antigen- Presenting Cells))	#12C 07 		

AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. §1.111

In response to the Official Action dated January 6, 2000, please amend the above-identified patent application as follows:

In the specification:

Page 1, after the paragraph stating "The disclosure of commonly-owned co-pending U.S. Application Serial No. 08/299,285, is incorporated by reference herein."

This application claims priority to PCT US96/16825, filed October 18, 1996 and U.S. Provisional Application No. 60/005,727, filed October 20, 1995, the entireties of which are incorporated by reference herein--.

Page 8, line 12: change "internvention" to --intervention--.

Page 30, line 34: change "decapetide" to --decapeptide-.



ATTORNEY DOCKET NO.: UNMC 63102/13292-00005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Sam D. Sanderson, et al Serial No.

09/051,685

Group Art Unit: 1644

Examiner:

F. VanderVegt

August 19, 1998 Filed:

For: Compositions and Methods

Enhancing Immune Responses by Antigen-Presenting Cells

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on the date indicated below.

BY:

Assistant Commissioner for Patents Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER AND REQUEST FOR EXTENSION OF TIME

Transmitted herewith is an amendment in the above-identified application.

Small entity status of this application under 37 CFR (X) 1.9 and 37 CFR 1.27 has been established by a verified statement previously submitted.

A verified statement claiming small entity status () under 37 CFR 1.9 and 37 CFR 1.27 is enclosed.

The fee for additional claims presented in this amendment has been calculated as follows:

06/13/2000 GTEFFERA 00000003 501089 09051685

01 FD:216

190.00 CH

509838.1 6/6/0

			Tadi.	SMATEL ENTIT	100		OTHER SMALL	
	Claims Remaining After Amendment	Highest Number Previously Paid for	No. Extra	Rate	Fee	<u>O</u> <u>R</u>	Rate	Fee
Total Claims	15	24	0	x\$9=	\$0	<u>O</u>	x\$18=	\$
Indep.	1	(at least 3)	0	x\$39 =	\$0	<u>O</u>	x\$78≖	\$
First Pr Dependen +	\$130 =	\$0	<u>O</u> <u>R</u>	\$260=	\$			
Total fee for added claims:					\$0			ģ.

Request is hereby made under 37 CFR 1.136(a) to extend the time for response to the Office Action of January 6, 2000 to and through <u>June 6, 2000</u>, comprising an extension of the shortened period of <u>2</u> month(s):

	SMALL EN	SMALL ENTITY		SMALL: O
One Month		\$ 55		\$ 210
Two Months	х	\$190		\$ 380
Three Months		\$435		\$ 870
Four Months		\$680		\$1,360
Additional fee for	extended resp	oonse:		

Applicant(s) has/have not been notified that the requested extension will not be permitted. The present application is not involved in an interference declared pursuant to 37 CFR 1.207.

Total fee required

Please charge my Deposit Account No. 50-1089 in the amount

et in the	
	of \$190.00 . This sheet is attached in duplicate.
() An extension for has already been secured and the fee paid therefore of \$ is deducted from the total fee due for the total months of extension now requested. Extension fee due with this request
	\$
() A check in the amount of \$\frac{\state}{2}\$ is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1089.
(XX	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1089. This sheet is attached in duplicate.
	(XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.
	(XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).
(XX	The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 50-1089. This sheet is attached in duplicate.
	(XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).
	() The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
(XX	Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.
Dat	Signature
Cer 150 Phi	Janet E. Reed, Ph.D., Registration No. 36,252 July EWING REMICK & SAUL LLP Atre Square West Market Street, 38th Floor Lladelphia, PA 19102 July Property of the property